We are live on ! Find out more
RAPT

RAPT Therapeutics
RAPT

Delisted

RAPT was delisted on the 2nd of March, 2026.

Back to rankings

0 hedge funds and large institutions have $0 invested in RAPT Therapeutics in 2026 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 104 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 105 → 0 (-105)

100% less funds holding in top 10

Funds holding in top 10: 9 → 0 (-9)

100% less capital invested

Capital invested by funds: $1.02B → $0 (-$1.02B)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 104

109.39% less ownership

Funds ownership: 109.39% → 0% (-109%)

Holders
–
Holders Change
-105
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-9
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
104
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
MVM
Medicxi Ventures Management
Jersey
-$94.6M
2
TCM
TCG Crossover Management
California
-$87.5M
3
FIS
FCPM III Services
Netherlands
-$62.1M
4
O
OrbiMed
New York
-$55.6M
5
RI
RTW Investments
New York
-$55.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
26
Fidelity Investments
Massachusetts
– -$9.34M -275,758 Closed
Adage Capital Partners
27
Adage Capital Partners
Massachusetts
– -$9.31M -275,000 Closed
Goldman Sachs
28
Goldman Sachs
New York
– -$8.6M -254,053 Closed
CC
29
Commodore Capital
New York
– -$8.47M -250,000 Closed
Geode Capital Management
30
Geode Capital Management
Massachusetts
– -$8.13M -239,790 Closed
RSCM
31
Rock Springs Capital Management
Maryland
– -$7.24M -213,731 Closed
Invesco
32
Invesco
Georgia
– -$5.66M -167,030 Closed
AIC
33
AWM Investment Company
New York
– -$5.51M -162,560 Closed
Qube Research & Technologies (QRT)
34
Qube Research & Technologies (QRT)
United Kingdom
– -$5.36M -158,292 Closed
CG
35
Column Group
California
– -$5.29M -156,270 Closed
OM
36
Opaleye Management
Massachusetts
– -$213K -150,000 Closed
TAM
37
TFG Asset Management
Cayman Islands
– -$4.46M -131,770 Closed
DTC
38
Deep Track Capital
Connecticut
– -$3.74M -110,448 Closed
VCIM
39
Velan Capital Investment Management
Georgia
– -$3.66M -108,000 Closed
Millennium Management
40
Millennium Management
New York
– -$3.61M -106,671 Closed
ACM
41
Atika Capital Management
New York
– -$3.19M -94,245 Closed
Renaissance Technologies
42
Renaissance Technologies
New York
– -$3.09M -91,173 Closed
Jane Street
43
Jane Street
New York
– -$2.87M -84,778 Closed
Marshall Wace
44
Marshall Wace
United Kingdom
– -$2.87M -84,596 Closed
EC
45
Euclidean Capital
New York
– -$2.79M -82,234 Closed
Barclays
46
Barclays
United Kingdom
– -$2.6M -76,659 Closed
UBS Group
47
UBS Group
Switzerland
– -$2.24M -66,225 Closed
Bank of America
48
Bank of America
North Carolina
– -$1.98M -58,330 Closed
QC
49
Quadrature Capital
United Kingdom
– -$1.95M -57,590 Closed
TI
50
Trexquant Investment
Connecticut
– -$1.83M -54,016 Closed
1
2
3 4 5

RAPT Hedge Fund Activity: Q1 2026 in Review

0 of the 8,127 institutional investors tracked by Wall St. Rank reported a position in RAPT Therapeutics (RAPT) for Q1 2026, worth a combined $0 — down 100% from $1.02B a quarter earlier.

Sellers outnumbered buyers: 104 funds closed out of RAPT and 0 opened new positions — a net loss of 104 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Medicxi Ventures Management, exiting entirely with an estimated $94.6M sold.

  • 0 institutional investors held RAPT Therapeutics (RAPT) as of Q1 2026, down from 105 in Q4 2025.
  • Funds reported $0 of RAPT Therapeutics stock for Q1 2026, down 100% quarter-over-quarter.
  • 0 funds opened new RAPT Therapeutics positions in Q1 2026 and 104 closed out, a net change of -104 holders.
  • The largest RAPT Therapeutics seller in Q1 2026 was Medicxi Ventures Management, an estimated $94.6M sold.

Based on aggregated 13F filings for Q1 2026.